- Home
- VRPX
as 07-26-2024 4:00pm EST
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BERWYN |
| Market Cap: | 1.6M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 18.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $9.50 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Virpax Pharmaceuticals Inc. News
VRPX Breaking Stock News: Dive into VRPX Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Virpax Regains Compliance with Nasdaq Minimum Bid Price
Benzinga
16 days ago
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?
MT Newswires
16 days ago
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise
Business Wire
17 days ago
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
Business Wire
19 days ago
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
Business Wire
2 months ago
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
MT Newswires
2 months ago
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble
MT Newswires
2 months ago
Top Premarket Decliners
Compare VRPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRPX Virpax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.